Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2023

Open Access 01-12-2023 | Mesothelioma | Research

A postmortem case control study of asbestos burden in lungs of malignant mesothelioma cases

Authors: S. D. Visonà, B. Bertoglio, C. Favaron, S. Capella, E. Belluso, C. Colosio, S. Villani, T. Ivic-Pavlicic, E. Taioli

Published in: Journal of Translational Medicine | Issue 1/2023

Login to get access

Abstract

Background

Asbestos lung content is regarded as the most reliable tool for causal attribution of malignant mesothelioma (MM) to previous asbestos exposures. However, there is a lack of studies on asbestos burden in lungs of MM patients in comparison with healthy individuals. This study aims to provide such a comparison, investigating, as well, differences in asbestos lung burden with sex and time trends.

Methods

Asbestos lung content has been assessed on formalin-fixed lung fragments using scanning electron microscopy coupled with energy dispersion spectroscopy (SEM–EDS) on individuals deceased from MM (cases) and healthy subjects without any lung disease who died from violent causes (controls) between 2005 and 2023.

Results

Asbestos and asbestos bodies (ABs) were found, respectively, in 73.7% and 43.2% of cases and in 28 and 22% of controls; in MM cases the most represented asbestos types were crocidolite and amosite, whereas in controls it was tremolite-actinolite asbestos. The concentration of both asbestos fibers and ABs was statistically significantly higher in MM cases compared to controls. The mean asbestos fibers width was also significantly higher in cases than controls. Males and females with MM showed similar asbestos and ABs concentrations, but females had higher concentrations of chrysotile, and significantly lower fibers width compared to males. Time trends show that MM lung asbestos concentrations decreased starting in 2011.

Discussion

The results suggest a correlation between asbestos burden in lungs and MM risk. The different concentration of chrysotile, as well as the different width of asbestos fibers in MM males and females might reflect a sex difference in response of the lung microenvironment to inhaled asbestos. Finally, this study provides the first pathological evidence of the effect of the ban of asbestos use, demonstrating a significant decrease of asbestos lung content after 2011.
Appendix
Available only for authorised users
Literature
1.
Carbone M, Adusumilli PS, Alexander HR Jr, Baas P, Bardelli F, Bononi A, et al. Mesothelioma: scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin. 2019;69(5):402–29.PubMedPubMedCentralCrossRef
2.
IARC. Asbestos: IARC monographs on the evaluation of carcinogenic risks to humans. Geneva: World Health Organization; 1977. p. 108.
3.
Chiappino G, Sebastien P, Todaro A. Atmospheric asbestos pollution in the urban environment: Milan, Casale Monferrato, Brescia, Ancona, Bologna and Florence. Med Lav. 1991;82(5):424–38.PubMed
4.
Casali M, Carugno M, Cattaneo A, Consonni D, Mensi C, Genovese U, et al. Asbestos lung burden in necroscopic samples from the general population of Milan. Italy Ann Occup Hyg. 2015;59(7):909–21.PubMedCrossRef
5.
Capella S, Bellis D, Fioretti E, Marinelli R, Belluso E. Respirable inorganic fibers dispersed in air and settled in human lung samples: assessment of their nature, source, and concentration in a NW Italy large city. Environ Pollut. 2020;263(Pt B):114384.PubMedCrossRef
6.
7.
Dodson RF, O’Sullivan M, Corn CJ, McLarty JW, Hammar SP. Analysis of asbestos fiber burden in lung tissue from mesothelioma patients. Ultrastruct Pathol. 1997;21(4):321–36.PubMedCrossRef
8.
Roggli VL, Sanders LL. Asbestos content of lung tissue and carcinoma of the lung: a clinicopathologic correlation and mineral fiber analysis of 234 cases. Ann Occup Hyg. 2000;44(2):109–17.PubMedCrossRef
9.
Churg A, Wright JL, Vedal S. Fiber burden and patterns of asbestos-related disease in chrysotile miners and millers. Am Rev Respir Dis. 1993;148(1):25–31.PubMedCrossRef
10.
Howel D, Gibbs A, Arblaster L, Swinburne L, Schweiger M, Renvoize E, et al. Mineral fibre analysis and routes of exposure to asbestos in the development of mesothelioma in an English region. Occup Environ Med. 1999;56(1):51–8.PubMedPubMedCentralCrossRef
11.
Churg A, Wiggs B. Fiber size and number in workers exposed to processed chrysotile asbestos, chrysotile miners, and the general population. Am J Ind Med. 1986;9(2):143–52.PubMedCrossRef
12.
McDonald JC, Armstrong BG, Edwards CW, Gibbs AR, Lloyd HM, Pooley FD, et al. Case-referent survey of young adults with mesothelioma: I lung fibre analyses. Ann Occup Hyg. 2001;45(7):513–8.PubMedCrossRef
13.
Visonà SD, Crespi E, Belluso E, Capella S, De Matteis S, Filippi F, et al. Reconstructing historical exposure to asbestos: the validation of “educated guesses.” Occup Med. 2022;72(8):534–40.CrossRef
14.
Selikoff IJ, Lee DHK. Asbestos and disease. Cambridge: Academic Press; 1978. p. 549.
15.
Visonà SD, Capella S, Bodini S, Borrelli P, Villani S, Crespi E, et al. Reply to Mirabelli et al. Is Mesothelioma Unrelated to the Lung Asbestos Burden? Comment on “Visonà et al. Inorganic Fiber Lung Burden in Subjects with Occupational and/or Anthropogenic Environmental Asbestos Exposure in Broni (Pavia, Northern Italy): An SEM-EDS Study on Autoptic Samples. Int. J. Environ. Res. Public Health 2021, 18, 2053.” Int J Environ Res Public Health. 2021 Jul 5;18(13). https://​doi.​org/​10.​3390/​ijerph18137181
16.
Marinaccio A, Corfiati M, Binazzi A, Di Marzio D, Scarselli A, Ferrante P, et al. The epidemiology of malignant mesothelioma in women: gender differences and modalities of asbestos exposure. Occup Environ Med. 2018;75(4):254–62.PubMedCrossRef
17.
18.
Husain AN, Colby TV, Ordóñez NG, Allen TC, Attanoos RL, Beasley MB, et al. Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the international mesothelioma interest group. Arch Pathol Lab Med. 2018;142(1):89–108.PubMedCrossRef
19.
Husain AN, Colby TV, Ordóñez NG, Krausz T, Borczuk A, Cagle PT, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the international mesothelioma interest group. Arch Pathol Lab Med. 2009;133(8):1317–31.PubMedCrossRef
20.
Wolff H, Vehmas T, Oksa P, Rantanen J, Vainio H. Asbestos, asbestosis, and cancer, the Helsinki criteria for diagnosis and attribution 2014: recommendations. Scand J Work Environ Health. 2015;41(1):5–15.PubMedCrossRef
21.
Asbestos, asbestosis, and cancer: the Helsinki criteria for diagnosis and attribution. Scand J Work Environ Health. 1997; 23(4):311–6.
22.
Oddone E, Ferrante D, Cena T, Tùnesi S, Amendola P, Magnani C. Asbestos cement factory in Broni (Pavia, Italy): a mortality study. Med Lav. 2014;105(1):15–29.PubMed
23.
Oddone E, Ferrante D, Tunesi S, Magnani C. Mortality in asbestos cement workers in Pavia, Italy: a cohort study. Am J Ind Med. 2017;60(10):852–66.PubMedCrossRef
24.
World Health Organization. Regional Office for Europe. Air quality guidelines for Europe. Copenhagen: WHO Regional Office for Europe; 2000.
25.
Belluso E, Bellis D, Fornero E, Capella S, Ferraris G, Coverlizza S. Assessment of inorganic fibre burden in biological samples by scanning electron microscopy—energy dispersive spectroscopy. Microchim Acta. 2006;155(1):95–100.CrossRef
26.
Visonà SD, Capella S, Bodini S, Borrelli P, Villani S, Crespi E, et al. Evaluation of deposition and clearance of asbestos (detected by SEM-EDS) in lungs of deceased subjects environmentally and/or occupationally exposed in Broni (Pavia, Northern Italy). Front Public Health. 2021;9:980.CrossRef
27.
Suzuki Y, Yuen SR, Ashley R. Short, thin asbestos fibers contribute to the development of human malignant mesothelioma: pathological evidence. Int J Hyg Environ Health. 2005;208(3):201–10.PubMedCrossRef
28.
Berman DW, Crump KS. A meta-analysis of asbestos-related cancer risk that addresses fiber size and mineral type. Crit Rev Toxicol. 2008;38(Suppl 1):49–73.PubMedCrossRef
29.
Boulanger G, Andujar P, Pairon JC, Billon-Galland MA, Dion C, Dumortier P, et al. Quantification of short and long asbestos fibers to assess asbestos exposure: a review of fiber size toxicity. Environ Health. 2014;21(13):59.CrossRef
30.
Gruppo Biofibre. Corpuscoli dell’asbesto nel tessuto polmonare umano e liquidi biologici: metodo analitico e atlante fotografico. Istituto Superiore di Sanità; 2017. Accessed 2 May 2023.
31.
32.
Oury TD, Sporn TA, Roggli VL. Pathology of asbestos-associated diseases. 3rd ed. Verlag Berlin Heidelberg: Springer; 2014.CrossRef
33.
Dodson RF, Hammar SP. Asbestos: risk assessment, epidemiology and health effects. 6000 broken sound parkway NW, SUite 300. Boca Raton: CRC Press, Taylor and Francis Group; 2011.CrossRef
34.
35.
36.
Churg A, DePaoli L. Clearance of chrysotile asbestos from human lung. Exp Lung Res. 1988;14(5):567–74.PubMedCrossRef
37.
Churg A. Deposition and clearance of chrysotile asbestos. Ann Occup Hyg. 1994;38(4):625–33.PubMed
38.
Toyokuni S. Iron addiction with ferroptosis-resistance in asbestos-induced mesothelial carcinogenesis: toward the era of mesothelioma prevention. Free Radic Biol Med. 2019;133:206–15.PubMedCrossRef
39.
Churg A, Warnock ML. Correlation of quantitative asbestos body counts and occupation in urban patients. Arch Pathol Lab Med. 1977;101(12):629–34.PubMed
40.
Case BW, Sebastien P, McDonald JC. Lung fiber analysis in accident victims: a biological assessment of general environmental exposures. Arch Environ Health. 1988;43(2):178–9.PubMedCrossRef
41.
Breedin PH, Buss DH. Ferruginous (asbestos) bodies in the lungs of rural dwellers, urban dwellers, and patients with pulmonary neoplasms. South Med J. 1976;69(4):401–4.PubMedCrossRef
42.
Rogers AJ, Leigh J, Berry G, Ferguson DA, Mulder HB, Ackad M. Relationship between lung asbestos fiber type and concentration and relative risk of mesothelioma. A case-control study. Cancer. 1991;67(7):1912–20.PubMedCrossRef
43.
Sakai K, Hisanaga N, Huang J, Shibata E, Ono Y, Aoki T, et al. Asbestos and nonasbestos fiber content in lung tissue of Japanese patients with malignant mesothelioma. Cancer. 1994;73(7):1825–35.PubMedCrossRef
44.
Gilham C, Rake C, Burdett G, Nicholson AG, Davison L, Franchini A, et al. Pleural mesothelioma and lung cancer risks in relation to occupational history and asbestos lung burden. Occup Environ Med. 2016;73(5):290–9.PubMedCrossRef
45.
46.
Gordon RE, Fitzgerald S, Millette J. Asbestos in commercial cosmetic talcum powder as a cause of mesothelioma in women. Int J Occup Environ Health. 2014;20(4):318–32.PubMedPubMedCentralCrossRef
47.
Barbieri PG, Somigliana A, Chen Y, Consonni D, Vignola R, Finotto L. Lung asbestos fibre burden and pleural mesothelioma in women with non-occupational exposure. Ann Work Expo Health. 2020;64(3):297–310.PubMedCrossRef
48.
Consonni D, De Matteis S, Dallari B, Pesatori AC, Riboldi L, Mensi C. Impact of an asbestos cement factory on mesothelioma incidence in a community in Italy. Environ Res. 2020;183: 108968.PubMedCrossRef
49.
Marsh GM, Riordan AS, Keeton KA, Benson SM. Non-occupational exposure to asbestos and risk of pleural mesothelioma: review and meta-analysis. Occup Environ Med. 2017;74(11):838–46.PubMedCrossRef
50.
Xu R, Barg FK, Emmett EA, Wiebe DJ, Hwang WT. Association between mesothelioma and non-occupational asbestos exposure: systematic review and meta-analysis. Environ Health. 2018;17(1):90.PubMedPubMedCentralCrossRef
51.
Roggli VL, Sharma A, Butnor KJ, Sporn T, Vollmer RT. Malignant mesothelioma and occupational exposure to asbestos: a clinicopathological correlation of 1445 cases. Ultrastruct Pathol. 2002;26(2):55–65.PubMedCrossRef
52.
Hodgson JT, Darnton A. The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure. Ann Occup Hyg. 2000;44(8):565–601.PubMedCrossRef
53.
Germine M, Puffer JH. Analytical transmission electron microscopy of amphibole fibers from the lungs of quebec miners. Arch Environ Occup Health. 2015;70(6):323–31.PubMedCrossRef
54.
Laaksonen S, Kettunen E, Sutinen E, Ilonen I, Vehmas T, Törmäkangas T, et al. Pulmonary asbestos fiber burden is related to patient survival in malignant pleural mesothelioma. J Thorac Oncol. 2022;17(8):1032–41.PubMedCrossRef
55.
Barbieri PG, Consonni D, Somigliana A. Asbestos lung burden does not predict survival in malignant pleural mesothelioma: a necropsy-based study of 185 cases. J Thorac Oncol. 2022;17(8):1042–9.PubMedCrossRef
56.
Huang J, Chan SC, Pang WS, Chow SH, Lok V, Zhang L, et al. Global incidence, risk factors, and temporal trends of mesothelioma: a population-based study. J Thorac Oncol. 2023;18(6):792–802.PubMedCrossRef
57.
Walker-Bone K, Benke G, MacFarlane E, Klebe S, Takahashi K, Brims F, et al. Incidence and mortality from malignant mesothelioma 1982–2020 and relationship with asbestos exposure: the Australian mesothelioma registry. Occup Environ Med. 2023;80(4):186–91.PubMedCrossRef
Metadata
Title
A postmortem case control study of asbestos burden in lungs of malignant mesothelioma cases
Authors
S. D. Visonà
B. Bertoglio
C. Favaron
S. Capella
E. Belluso
C. Colosio
S. Villani
T. Ivic-Pavlicic
E. Taioli
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2023
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-023-04761-9

Other articles of this Issue 1/2023

Journal of Translational Medicine 1/2023 Go to the issue

Research

Predicting tumor repopulation through the gene panel derived from radiation resistant colorectal cancer cells

Research

FASN multi-omic characterization reveals metabolic heterogeneity in pancreatic and prostate adenocarcinoma

Research

Harnessing large language models (LLMs) for candidate gene prioritization and selection

Research

The HIFIA/LINC02913/IGF1R axis promotes the cell function of adipose-derived mesenchymal stem cells under hypoxia via activating the PI3K/AKT pathway

Research

Leveraging a cuproptosis-based signature to predict the prognosis and drug sensitivity of cutaneous melanoma

Research

Cell–cell communications shape tumor microenvironment and predict clinical outcomes in clear cell renal carcinoma
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits